ArticleNature communications2026
Selective deoxygenative bis- and monoborylation of carboxylic esters via boryloxy chromium-carbenes.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fischer-type metal carbenes are versatile intermediates that mediate a wide array of molecular transformations. However, their classical synthesis typically requires stoichiometric amounts of chromium and hazardous reagents such as diazo compounds or organolithium species, posing significant safety and operational concerns. A recent copper- and palladium-catalyzed Brook rearrangement of aroylsilanes opened a catalytic strategy to alleviate these problems. Herein, we report a complementary strategy that enables catalytic deoxygenative borylation of carboxylic esters under conditions consistent with the intermediacy of boryloxy chromium-carbene species, enabled by a combination of pinacolborane, magnesium metal, and a chromium catalyst. The reaction converts the ester to either bis- or monoboryl alkanes-valuable intermediates for further synthetic diversification-depending on the choice of bipyridine or terpyridine ligand. Multiple lines of evidence, including cyclopropanation, deuterium quenching, and DFT analysis, support a low-energy pathway involving chromium-carbene intermediates. The ligand-controlled bifurcation arises from subtle energy differences between quintet and triplet pathways, elucidated by the DFT calculations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.